A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.

Inclusion Criteria: * 1\. Read, understood, and signed an ICF before any investigational procedure(s) are performed.. 2\. Male or female aged 18 to 45 (including threshold). 3. For male participants, the body weight should be ≥ 50.0 kg, and for female paticipants, the body weight should be ≥ 45.0 kg. The body mass index (BMI) should be within the range of 19.0 to 26.0 kg/m²(including threshold) 4. Results of vital signs examination, physical examination, clinical laboratory tests (including blood routine examination, urine routine examination, blood biochemistry examination, coagulation function examination, thyroid function examination, etc.), chest X-ray, adrenal gland color ultrasound, etc. during the screening period show normal results or, if there are abnormalities, they are judged by the investigator to have no clinical significance.. 5\. Be willing to avoid pregnancy or voluntarily take effective contraceptive measures and have no sperm or egg donation plan from the signing of the informed consent form to three month after the last administration of the investigational medicinal product. 6\. Be able to communicate well with the investigator and understand and comply with the requirements of the study. Exclusion Criteria: * 1\. Participants with clinically significant abnormal electrocardiogram results judged by the investigator during screening. 2\. Participants known to be allergic to this product or related excipients; or participants with an allergic…